These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 23148949)

  • 1. Pharmacological profile of engineered 5-HT₄ receptors and identification of 5-HT₄ receptor-biased ligands.
    Gaven F; Pellissier LP; Queffeulou E; Cochet M; Bockaert J; Dumuis A; Claeysen S
    Brain Res; 2013 May; 1511():65-72. PubMed ID: 23148949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modifying ligand-induced and constitutive signaling of the human 5-HT4 receptor.
    Chang WC; Ng JK; Nguyen T; Pellissier L; Claeysen S; Hsiao EC; Conklin BR
    PLoS One; 2007 Dec; 2(12):e1317. PubMed ID: 18338032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into the human 5-HT4 receptor binding site: exploration of a hydrophobic pocket.
    Rivail L; Giner M; Gastineau M; Berthouze M; Soulier JL; Fischmeister R; Lezoualc'h F; Maigret B; Sicsic S; Berque-Bestel I
    Br J Pharmacol; 2004 Oct; 143(3):361-70. PubMed ID: 15351779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single mutation in the 5-HT4 receptor (5-HT4-R D100(3.32)A) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL).
    Claeysen S; Joubert L; Sebben M; Bockaert J; Dumuis A
    J Biol Chem; 2003 Jan; 278(2):699-702. PubMed ID: 12441358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant 5-hydroxytryptamine 1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology.
    Cussac D; Palmier C; Finana F; De Vries L; Tardif S; Léger C; Bernois S; Heusler P
    J Pharmacol Exp Ther; 2009 Oct; 331(1):222-33. PubMed ID: 19605522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin type 4 receptor dimers.
    Claeysen S; Donneger R; Giannoni P; Gaven F; Pellissier LP
    Methods Cell Biol; 2013; 117():123-39. PubMed ID: 24143975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigations into the binding affinities of different human 5-HT4 receptor splice variants.
    Irving HR; Tochon-Danguy N; Chinkwo KA; Li JG; Grabbe C; Shapiro M; Pouton CW; Coupar IM
    Pharmacology; 2010; 85(4):224-33. PubMed ID: 20299822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Creation, expression, and characterization of a constitutively active mutant of the human serotonin 5-HT6 receptor.
    Purohit A; Herrick-Davis K; Teitler M
    Synapse; 2003 Mar; 47(3):218-24. PubMed ID: 12494404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenoxybenzamine and benextramine, but not 4-diphenylacetoxy-N-[2-chloroethyl]piperidine hydrochloride, display irreversible noncompetitive antagonism at G protein-coupled receptors.
    Bodenstein J; Venter DP; Brink CB
    J Pharmacol Exp Ther; 2005 Aug; 314(2):891-905. PubMed ID: 15857948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 8-hydroxy-2-(di-n-propylamino)tetralin-responsive 5-hydroxytryptamine4-like receptor expressed in bovine pulmonary artery smooth muscle cells.
    Becker BN; Gettys TW; Middleton JP; Olsen CL; Albers FJ; Lee SL; Fanburg BL; Raymond JR
    Mol Pharmacol; 1992 Nov; 42(5):817-25. PubMed ID: 1331764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-HT induces duodenal mucosal bicarbonate secretion via cAMP- and Ca2+-dependent signaling pathways and 5-HT4 receptors in mice.
    Tuo BG; Sellers Z; Paulus P; Barrett KE; Isenberg JI
    Am J Physiol Gastrointest Liver Physiol; 2004 Mar; 286(3):G444-51. PubMed ID: 14576083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-HT(4) receptors: history, molecular pharmacology and brain functions.
    Bockaert J; Claeysen S; Compan V; Dumuis A
    Neuropharmacology; 2008 Nov; 55(6):922-31. PubMed ID: 18603269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inverse agonist activity of selected ligands of platelet-activating factor receptor.
    Dupré DJ; Le Gouill C; Rola-Pleszczynski M; Stanková J
    J Pharmacol Exp Ther; 2001 Oct; 299(1):358-65. PubMed ID: 11561099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT4 and 5-HT2 receptors antagonistically influence gap junctional coupling between rat auricular myocytes.
    Derangeon M; Bozon V; Defamie N; Peineau N; Bourmeyster N; Sarrouilhe D; Argibay JA; Hervé JC
    J Mol Cell Cardiol; 2010 Jan; 48(1):220-9. PubMed ID: 19615378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominant-negative activity of an alpha(1B)-adrenergic receptor signal-inactivating point mutation.
    Chen S; Lin F; Xu M; Hwa J; Graham RM
    EMBO J; 2000 Aug; 19(16):4265-71. PubMed ID: 10944109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel 5-HT(4) receptor splice variant (r5-HT(4c1)) and preliminary characterisation of specific 5-HT(4a) and 5-HT(4b) receptor antibodies.
    Ray AM; Kelsell RE; Houp JA; Kelly FM; Medhurst AD; Cox HM; Calver AR
    Eur J Pharmacol; 2009 Feb; 604(1-3):1-11. PubMed ID: 19100256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists.
    Brudeli B; Moltzau LR; Andressen KW; Krobert KA; Klaveness J; Levy FO
    Bioorg Med Chem; 2010 Dec; 18(24):8600-13. PubMed ID: 21075638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of the human 5-HT(4(d)) receptor splice variant stably expressed in Chinese hamster ovary cells.
    Mialet J; Berque-Bestel I; Sicsic S; Langlois M; Fischmeister R; Lezoualc'h F
    Br J Pharmacol; 2000 Oct; 131(4):827-35. PubMed ID: 11030734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G protein activation by serotonin type 4 receptor dimers: evidence that turning on two protomers is more efficient.
    Pellissier LP; Barthet G; Gaven F; Cassier E; Trinquet E; Pin JP; Marin P; Dumuis A; Bockaert J; Banères JL; Claeysen S
    J Biol Chem; 2011 Mar; 286(12):9985-97. PubMed ID: 21247891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties.
    Moser PC; Bergis OE; Jegham S; Lochead A; Duconseille E; Terranova JP; Caille D; Berque-Bestel I; Lezoualc'h F; Fischmeister R; Dumuis A; Bockaert J; George P; Soubrié P; Scatton B
    J Pharmacol Exp Ther; 2002 Aug; 302(2):731-41. PubMed ID: 12130738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.